利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.026 秒)

    PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF CANCER
    4.
    发明申请
    PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF CANCER 审中-公开
    用于治疗癌症的PHYTOCANNABINOIDS

    公开(公告)号：US20140221469A1

    公开(公告)日：2014-08-07

    申请号：US14343877

    申请日：2012-09-10

    申请人： Ruth Alexandra Ross ,  Daniela Parolaro

    发明人： Ruth Alexandra Ross ,  Daniela Parolaro

    IPC分类号： A61K31/352 ,  A61K31/235 ,  A61K31/05

    CPC分类号： A61K31/352 ,  A61K31/05 ,  A61K31/192 ,  A61K31/235 ,  A61K31/353 ,  A61K2300/00

    摘要： The present invention relates to the use of phytocannabinoids in the treatment of cancer. More particularly it relates to the use of phytocannabinoids in the treatment of tumour cell invasion and cell migration or metastases. Cancers, where invasion and cell migration plays a key role in prognosis include brain tumours, more particularly gliomas, and most particularly Glioblastoma multiforme (GBM) and breast cancers. The phytocannabinoids tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV) alone or in combination with each other and/or other phytocannabinoids, particularly cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG) or their respective acids are of particular use.

    摘要翻译： 本发明涉及植物大麻素在癌症治疗中的应用。 更具体地说，它涉及植物大麻素在治疗肿瘤细胞侵袭和细胞迁移或转移中的应用。 侵袭和细胞迁移在预后中起关键作用的癌症包括脑肿瘤，尤其是神经胶质瘤，特别是多形性成胶质细胞瘤（GBM）和乳腺癌。 单独使用或与其他植物大变性动物，特别是大麻二酚（CBD），四氢大麻酚（THC）和大麻酚（CBG）或其各自的酸组合的植物大丁素四氢大戟素（THCV）和大麻素（CBDV））是特别有用的。

    1,5-Diaryl-Pyrazoles As Cannabinoid Receptor Neutral Antagonists Useful As Therapeutic Agents
    5.
    发明申请
    1,5-Diaryl-Pyrazoles As Cannabinoid Receptor Neutral Antagonists Useful As Therapeutic Agents 审中-公开
    1,5-二芳基吡唑作为大麻素受体中性拮抗剂有用作治疗剂

    公开(公告)号：US20100022611A1

    公开(公告)日：2010-01-28

    申请号：US12525002

    申请日：2008-02-07

    申请人： Iain Robert Greig ,  Ruth Alexandra Ross ,  Roger Guy Pertwee

    发明人： Iain Robert Greig ,  Ruth Alexandra Ross ,  Roger Guy Pertwee

    IPC分类号： A61K31/415 ,  C07D231/10 ,  A61P3/00 ,  A61P25/00 ,  A61P19/00 ,  A61P29/00 ,  A61P37/00

    CPC分类号： C07D231/12

    摘要： The present invention pertains to cannabinoid (CB) receptor neutral antagonists, and especially CB1 neutral antagonists, and including, for example, certain 1,5-di-aryl-pyrazole compounds. The present invention also pertains to the use of such compounds in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of the cannabinoid type 1 (CB1) receptor, for example: an eating disorder; obesity; a disease or disorder characterised by an addiction component; addiction; withdrawal; smoking addiction; smoking withdrawal; drug addiction; drug withdrawal; smoking cessation therapy; a bone disease or disorder; osteoporosis, Paget's disease of bone; bone related cancer; a disease or disorder with an inflammatory or autoimmune component; rheumatoid arthritis; inflammatory bowel disease; psoriasis; a psychiatric disease or disorder; anxiety; mania; schizophrenia; a disease or disorder characterised by impairment of memory and/or loss of cognitive function; memory impairment; loss of cognitive function; Parkinson's disease; Alzheimer's disease; dementia; a cardiovascular disease or disorder; congestive heart failure; cardiac hypertrophy; and myocardial infarction.

    摘要翻译： 本发明涉及大麻素（CB）受体中性拮抗剂，特别是CB1中性拮抗剂，并且包括例如某些1,5-二芳基吡唑化合物。 本发明还涉及这种化合物在治疗通过用大麻素1型（CB1）受体的中性拮抗剂治疗而改善的疾病和病症的用途，例如：进食障碍; 肥胖; 以成瘾成分为特征的疾病或病症; 瘾; 退出; 吸烟成瘾; 戒烟 药物成瘾; 戒毒 戒烟治疗 骨病或病症; 骨质疏松症，佩吉特氏骨病; 骨相关癌症; 具有炎症或自身免疫组分的疾病或病症; 类风湿关节炎; 炎症性肠病; 银屑病; 精神疾病或病症; 焦虑; 狂躁; 精神分裂症 以记忆障碍和/或认知功能丧失为特征的疾病或病症; 记忆障碍 认知功能丧失; 帕金森病 阿尔茨海默氏病; 痴呆; 心血管疾病或病症; 充血性心力衰竭; 心脏肥大; 和心肌梗塞。